Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kestrel Therapeutics Inc.
Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors
September 15, 2026
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
May 27, 2026
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
May 16, 2026